Marieke Jansen is an experienced leader with legal expertise and a demonstrated history of working in the biotechnology industry. She is a specialist in Cell and Gene, Biopharmaceuticals, Biosimilars, Generics, Oncology, Global M&A, BD&L, TechOps, Corporate legal, Commercial, IP, Data Privacy and Compliance.
She joins PHC from Novartis, where she was head of Legal for Europe Cell and Gene Therapies at Novartis Oncology since 2018. Previously, she was senior Legal counsel at Novartis Technical Operations/BioTechnology. Her experience as Biotechnology company in-house counsel also includes Sandoz, where she was senior Legal counsel for five years, and Synthon, where she was global Legal counsel and deputy general counsel.
“I am very happy to share that I have started a new chapter in my career as general counsel EMEA/APAC with PHC Holdings Corporation. With many thanks to all colleagues and friends at Novartis, and especially the Cell and Gene team: it was a privilege to work, learn and grow together,” said Jansen.
The Japan-founded PHC Group is a leading diversified diagnostics, life sciences and medical device company serving global markets through Japanese excellence and precision, with a 2021 consolidated revenue of ¥306 billion (€2.26 billion), with 89 subsidiaries around the world.
